Sciclone Pharmaceut (SCLN) 10.88 $SCLN
Sciclone Pharmaceuticals Has Returned 70.9% Since SmarTrend Recommendation (SCLN)
Comtex SmarTrend(R) - Fri Jun 10, 12:40PM CDT
SmarTrend identified an Uptrend for Sciclone Pharmaceuticals (NASDAQ:SCLN) on November 9th, 2015 at $7.98. In approximately 7 months, Sciclone Pharmaceuticals has returned 70.93% as of today's recent price of $13.63.
SCLN: 10.88 (+0.32)
Shares of SCLN Up 74.2% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Fri Jun 03, 12:11AM CDT
SmarTrend identified an Uptrend for Sciclone Pharmaceuticals (NASDAQ:SCLN) on November 9th, 2015 at $7.98. In approximately 7 months, Sciclone Pharmaceuticals has returned 74.17% as of today's recent price of $13.89.
SCLN: 10.88 (+0.32)
Sciclone Pharmaceuticals Shares Up 62.9% Since SmarTrend's Buy Recommendation (SCLN)
Comtex SmarTrend(R) - Thu May 26, 12:40PM CDT
SmarTrend identified an Uptrend for Sciclone Pharmaceuticals (NASDAQ:SCLN) on November 9th, 2015 at $7.98. In approximately 7 months, Sciclone Pharmaceuticals has returned 62.88% as of today's recent price of $12.99.
SCLN: 10.88 (+0.32)
AWS Morning Technical Breakdown Highlights: Novo Nordisk, Biodel, Sucampo Pharma, and SciClone Pharma
ACCESSWIRE - Mon May 23, 8:16AM CDT
LONDON, UK / ACCESSWIRE / May 23, 2016 / ActiveWallSt.com announces the list of stocks featured in the Technical Morning Blog. Every morning the Active Wall St. team discusses the latest news and technical events impacting stocks and the financial markets. Companies recently featured in the blog include Novo Nordisk, Biodel, Sucampo Pharma, and SciClone Pharma.
NVO: 57.05 (+0.08), SCMP: 11.89 (+0.14), SCLN: 10.88 (+0.32), BIOD: 0.41 (-0.03)
Uptrend Call Working As Sciclone Pharmaceuticals Stock Rises 64.4% (SCLN)
Comtex SmarTrend(R) - Wed May 11, 12:42PM CDT
SmarTrend identified an Uptrend for Sciclone Pharmaceuticals (NASDAQ:SCLN) on November 9th, 2015 at $7.98. In approximately 6 months, Sciclone Pharmaceuticals has returned 64.39% as of today's recent price of $13.11.
SCLN: 10.88 (+0.32)
SciClone Reports First Quarter 2016 Financial Results
PR Newswire - Tue May 10, 5:00AM CDT
SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today reported financial results for the quarter ended March 31, 2016.
SCLN: 10.88 (+0.32)
SciClone Pharmaceuticals To Report First Quarter 2016 Financial Results On May 10, 2016
PR Newswire - Mon Apr 25, 5:00AM CDT
SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that it plans to report financial results for the first quarter 2016 on Tuesday, May 10, 2016. SciClone will host a conference call and webcast to provide a business and product update at 8:30 am ET (5:30 am PT) that day. The call will be hosted by Friedhelm Blobel, Ph.D., President and CEO, and Wilson W. Cheung, Senior Vice President and CFO.
SCLN: 10.88 (+0.32)
Shares of SCLN Up 62.5% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Tue Apr 19, 12:15AM CDT
SmarTrend identified an Uptrend for Sciclone Pharmaceuticals (NASDAQ:SCLN) on November 9th, 2015 at $7.98. In approximately 5 months, Sciclone Pharmaceuticals has returned 62.51% as of today's recent price of $12.96.
SCLN: 10.88 (+0.32)
Sciclone Pharmaceuticals Shares Up 55.3% Since SmarTrend's Buy Recommendation (SCLN)
Comtex SmarTrend(R) - Mon Apr 11, 12:38PM CDT
SmarTrend identified an Uptrend for Sciclone Pharmaceuticals (NASDAQ:SCLN) on November 9th, 2015 at $7.98. In approximately 5 months, Sciclone Pharmaceuticals has returned 55.30% as of today's recent price of $12.39.
SCLN: 10.88 (+0.32)
Shares of SCLN Up 37.6% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Fri Apr 01, 12:38PM CDT
SmarTrend identified an Uptrend for Sciclone Pharmaceuticals (NASDAQ:SCLN) on November 9th, 2015 at $7.98. In approximately 5 months, Sciclone Pharmaceuticals has returned 37.62% as of today's recent price of $10.98.
SCLN: 10.88 (+0.32)
Look for Shares of Sciclone Pharmaceuticals to Potentially Pullback after Yesterday's 13.34% Rise
Comtex SmarTrend(R) - Thu Mar 31, 3:35PM CDT
Sciclone Pharmaceuticals (NASDAQ:SCLN) traded in a range yesterday that spanned from a low of $10.35 to a high of $10.99. Yesterday, the shares gained 13.3%, which took the trading range above the 3-day high of $9.99 on volume of 1.3 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
SCLN: 10.88 (+0.32)
WebMD Health Set to Join the S&P MidCap 400; SciClone Pharmaceuticals to Join S&P SmallCap 600
PR Newswire - Wed Mar 30, 5:24PM CDT
S&P Dow Jones Indices will make the following changes to the S&P MidCap 400 and S&P SmallCap 600 indices after the close of trading on Friday, April 1:
WBMD: 60.91 (-0.10), TMO: 159.56 (+0.72), SUNE: 0.34 (unch), SCLN: 10.88 (+0.32), MHFI: 107.92 (+1.16), AFFX: 14.01 (+0.02)
SciClone To Present At Needham Healthcare Conference On April 13, 2016
PR Newswire - Wed Mar 30, 5:00AM CDT
FOSTER CITY, Calif., March 30, 2016 /PRNewswire/-- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that Wilson W. Cheung, Chief Financial Officer, will present a corporate overview and business update at the 15th Annual Needham Healthcare Conference at 8:00 am ET on Wednesday, April 13, 2016, at the Westin Grand Central Hotel in New York City.
SCLN: 10.88 (+0.32)
OxySure Therapeutics (OXYS) May Be Undervalued Compared to Others in Biotech Space
ACCESSWIRE - Mon Mar 21, 8:01AM CDT
REDONDO BEACH, CA / ACCESSWIRE / March 21, 2016 / OxySure Therapeutics Inc. (OTCQB: OXYS), developer of oxygen-from-powder technology and related medical solutions, has come a long way over the past year. Management anticipates reaching a $10 million annual run rate and achieving breakeven later this year. With 14 consecutive quarters of revenue growth, the company has a long track record of increasing shareholder value.
SRDX: 27.06 (-0.37), CFMS: 6.92 (-0.05), GKOS: 33.93 (-1.03), BEAT: 19.19 (+0.17), SCLN: 10.88 (+0.32)
SciClone Reports 2015 Financial Results
PR Newswire - Thu Mar 10, 3:05PM CST
SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today reported financial results for the quarter and year ended December 31, 2015.
SCLN: 10.88 (+0.32)
LifeSci Capital Initiates Coverage of SciClone
ACCESSWIRE - Tue Mar 08, 1:45PM CST
Profitable Specialty Pharmaceutical Company with Steady Revenue Growth; Report Available here: http://www.lifescicapital.com/equity-research/sciclone/
BAX: 48.50 (+0.48), PFE: 37.31 (+0.42), SCLN: 10.88 (+0.32)
27.3% Return Seen to Date on SmarTrend Sciclone Pharmaceuticals Call (SCLN)
Comtex SmarTrend(R) - Mon Mar 07, 5:13PM CST
SmarTrend identified an Uptrend for Sciclone Pharmaceuticals (NASDAQ:SCLN) on November 9th, 2015 at $7.98. In approximately 4 months, Sciclone Pharmaceuticals has returned 27.27% as of today's recent price of $10.15.
SCLN: 10.88 (+0.32)
Sciclone Pharmaceuticals Has Returned 70.9% Since SmarTrend Recommendation (SCLN)
Comtex SmarTrend(R) - Fri Jun 10, 12:40PM CDT
SmarTrend identified an Uptrend for Sciclone Pharmaceuticals (NASDAQ:SCLN) on November 9th, 2015 at $7.98. In approximately 7 months, Sciclone Pharmaceuticals has returned 70.93% as of today's recent price of $13.63.
SCLN: 10.88 (+0.32)
Shares of SCLN Up 74.2% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Fri Jun 03, 12:11AM CDT
SmarTrend identified an Uptrend for Sciclone Pharmaceuticals (NASDAQ:SCLN) on November 9th, 2015 at $7.98. In approximately 7 months, Sciclone Pharmaceuticals has returned 74.17% as of today's recent price of $13.89.
SCLN: 10.88 (+0.32)
Sciclone Pharmaceuticals Shares Up 62.9% Since SmarTrend's Buy Recommendation (SCLN)
Comtex SmarTrend(R) - Thu May 26, 12:40PM CDT
SmarTrend identified an Uptrend for Sciclone Pharmaceuticals (NASDAQ:SCLN) on November 9th, 2015 at $7.98. In approximately 7 months, Sciclone Pharmaceuticals has returned 62.88% as of today's recent price of $12.99.
SCLN: 10.88 (+0.32)
AWS Morning Technical Breakdown Highlights: Novo Nordisk, Biodel, Sucampo Pharma, and SciClone Pharma
ACCESSWIRE - Mon May 23, 8:16AM CDT
LONDON, UK / ACCESSWIRE / May 23, 2016 / ActiveWallSt.com announces the list of stocks featured in the Technical Morning Blog. Every morning the Active Wall St. team discusses the latest news and technical events impacting stocks and the financial markets. Companies recently featured in the blog include Novo Nordisk, Biodel, Sucampo Pharma, and SciClone Pharma.
NVO: 57.05 (+0.08), SCMP: 11.89 (+0.14), SCLN: 10.88 (+0.32), BIOD: 0.41 (-0.03)
Uptrend Call Working As Sciclone Pharmaceuticals Stock Rises 64.4% (SCLN)
Comtex SmarTrend(R) - Wed May 11, 12:42PM CDT
SmarTrend identified an Uptrend for Sciclone Pharmaceuticals (NASDAQ:SCLN) on November 9th, 2015 at $7.98. In approximately 6 months, Sciclone Pharmaceuticals has returned 64.39% as of today's recent price of $13.11.
SCLN: 10.88 (+0.32)
SciClone Reports First Quarter 2016 Financial Results
PR Newswire - Tue May 10, 5:00AM CDT
SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today reported financial results for the quarter ended March 31, 2016.
SCLN: 10.88 (+0.32)
SciClone Pharmaceuticals To Report First Quarter 2016 Financial Results On May 10, 2016
PR Newswire - Mon Apr 25, 5:00AM CDT
SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that it plans to report financial results for the first quarter 2016 on Tuesday, May 10, 2016. SciClone will host a conference call and webcast to provide a business and product update at 8:30 am ET (5:30 am PT) that day. The call will be hosted by Friedhelm Blobel, Ph.D., President and CEO, and Wilson W. Cheung, Senior Vice President and CFO.
SCLN: 10.88 (+0.32)
Shares of SCLN Up 62.5% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Tue Apr 19, 12:15AM CDT
SmarTrend identified an Uptrend for Sciclone Pharmaceuticals (NASDAQ:SCLN) on November 9th, 2015 at $7.98. In approximately 5 months, Sciclone Pharmaceuticals has returned 62.51% as of today's recent price of $12.96.
SCLN: 10.88 (+0.32)
Sciclone Pharmaceuticals Shares Up 55.3% Since SmarTrend's Buy Recommendation (SCLN)
Comtex SmarTrend(R) - Mon Apr 11, 12:38PM CDT
SmarTrend identified an Uptrend for Sciclone Pharmaceuticals (NASDAQ:SCLN) on November 9th, 2015 at $7.98. In approximately 5 months, Sciclone Pharmaceuticals has returned 55.30% as of today's recent price of $12.39.
SCLN: 10.88 (+0.32)
Shares of SCLN Up 37.6% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Fri Apr 01, 12:38PM CDT
SmarTrend identified an Uptrend for Sciclone Pharmaceuticals (NASDAQ:SCLN) on November 9th, 2015 at $7.98. In approximately 5 months, Sciclone Pharmaceuticals has returned 37.62% as of today's recent price of $10.98.
SCLN: 10.88 (+0.32)
Look for Shares of Sciclone Pharmaceuticals to Potentially Pullback after Yesterday's 13.34% Rise
Comtex SmarTrend(R) - Thu Mar 31, 3:35PM CDT
Sciclone Pharmaceuticals (NASDAQ:SCLN) traded in a range yesterday that spanned from a low of $10.35 to a high of $10.99. Yesterday, the shares gained 13.3%, which took the trading range above the 3-day high of $9.99 on volume of 1.3 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
SCLN: 10.88 (+0.32)
WebMD Health Set to Join the S&P MidCap 400; SciClone Pharmaceuticals to Join S&P SmallCap 600
PR Newswire - Wed Mar 30, 5:24PM CDT
S&P Dow Jones Indices will make the following changes to the S&P MidCap 400 and S&P SmallCap 600 indices after the close of trading on Friday, April 1:
WBMD: 60.91 (-0.10), TMO: 159.56 (+0.72), SUNE: 0.34 (unch), SCLN: 10.88 (+0.32), MHFI: 107.92 (+1.16), AFFX: 14.01 (+0.02)
SciClone To Present At Needham Healthcare Conference On April 13, 2016
PR Newswire - Wed Mar 30, 5:00AM CDT
FOSTER CITY, Calif., March 30, 2016 /PRNewswire/-- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that Wilson W. Cheung, Chief Financial Officer, will present a corporate overview and business update at the 15th Annual Needham Healthcare Conference at 8:00 am ET on Wednesday, April 13, 2016, at the Westin Grand Central Hotel in New York City.
SCLN: 10.88 (+0.32)
OxySure Therapeutics (OXYS) May Be Undervalued Compared to Others in Biotech Space
ACCESSWIRE - Mon Mar 21, 8:01AM CDT
REDONDO BEACH, CA / ACCESSWIRE / March 21, 2016 / OxySure Therapeutics Inc. (OTCQB: OXYS), developer of oxygen-from-powder technology and related medical solutions, has come a long way over the past year. Management anticipates reaching a $10 million annual run rate and achieving breakeven later this year. With 14 consecutive quarters of revenue growth, the company has a long track record of increasing shareholder value.
SRDX: 27.06 (-0.37), CFMS: 6.92 (-0.05), GKOS: 33.93 (-1.03), BEAT: 19.19 (+0.17), SCLN: 10.88 (+0.32)
SciClone Reports 2015 Financial Results
PR Newswire - Thu Mar 10, 3:05PM CST
SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today reported financial results for the quarter and year ended December 31, 2015.
SCLN: 10.88 (+0.32)
LifeSci Capital Initiates Coverage of SciClone
ACCESSWIRE - Tue Mar 08, 1:45PM CST
Profitable Specialty Pharmaceutical Company with Steady Revenue Growth; Report Available here: http://www.lifescicapital.com/equity-research/sciclone/
BAX: 48.50 (+0.48), PFE: 37.31 (+0.42), SCLN: 10.88 (+0.32)
27.3% Return Seen to Date on SmarTrend Sciclone Pharmaceuticals Call (SCLN)
Comtex SmarTrend(R) - Mon Mar 07, 5:13PM CST
SmarTrend identified an Uptrend for Sciclone Pharmaceuticals (NASDAQ:SCLN) on November 9th, 2015 at $7.98. In approximately 4 months, Sciclone Pharmaceuticals has returned 27.27% as of today's recent price of $10.15.
SCLN: 10.88 (+0.32)
